申请人:Zeneca Ltd.
公开号:US06258817B1
公开(公告)日:2001-07-10
The invention concerns pharmaceutically useful compounds of the formula I, in which A1, A2, A3, A4, B1, m, Ar, W, X, Y, Z and R1 have any of the meanings defined herein, and their pharmaceutically acceptable salts, and pharmaceutical compositions containing them. The novel compounds possess endothelin receptor antagonist activity and are useful, for example, in the treatment of diseases or medical conditions in which elevated or abnormal levels of endothelin play a significant causative role. The invention further concerns processes for the manufacture of the novel compounds and the use of the compounds in medical treatment.
本发明涉及公式I的药用化合物,其中A1、A2、A3、A4、B1、m、Ar、W、X、Y、Z和R1具有本说明书中定义的任何含义,以及它们的药学上可接受的盐和含有它们的药物组成物。这些新型化合物具有内皮素受体拮抗剂活性,例如,在治疗内皮素水平升高或异常发挥重要因果作用的疾病或医疗条件中有用。本发明还涉及制造新型化合物的过程以及化合物在医学治疗中的使用。